208 related articles for article (PubMed ID: 23162127)
1. The capsular polysaccharide Vi from Salmonella typhi is a B1b antigen.
Marshall JL; Flores-Langarica A; Kingsley RA; Hitchcock JR; Ross EA; López-Macías C; Lakey J; Martin LB; Toellner KM; MacLennan CA; MacLennan IC; Henderson IR; Dougan G; Cunningham AF
J Immunol; 2012 Dec; 189(12):5527-32. PubMed ID: 23162127
[TBL] [Abstract][Full Text] [Related]
2. Vi Capsular Polysaccharide Produced by Recombinant
Xiong K; Zhu C; Chen Z; Zheng C; Tan Y; Rao X; Cong Y
Front Cell Infect Microbiol; 2017; 7():135. PubMed ID: 28484685
[TBL] [Abstract][Full Text] [Related]
3. Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27+IgD-S. Typhi-specific IgA and IgG B memory cells in humans.
Wahid R; Pasetti MF; Maciel M; Simon JK; Tacket CO; Levine MM; Sztein MB
Clin Immunol; 2011 Feb; 138(2):187-200. PubMed ID: 21146460
[TBL] [Abstract][Full Text] [Related]
4. Salmonella Typhi OmpS1 and OmpS2 porins are potent protective immunogens with adjuvant properties.
Moreno-Eutimio MA; Tenorio-Calvo A; Pastelin-Palacios R; Perez-Shibayama C; Gil-Cruz C; López-Santiago R; Baeza I; Fernández-Mora M; Bonifaz L; Isibasi A; Calva E; López-Macías C
Immunology; 2013 Aug; 139(4):459-71. PubMed ID: 23432484
[TBL] [Abstract][Full Text] [Related]
5. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.
Singh M; Ganguly NK; Kumar L; Vohra H
Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549
[TBL] [Abstract][Full Text] [Related]
6. IgA and IgG1 Specific to Vi Polysaccharide of
Dahora LC; Jin C; Spreng RL; Feely F; Mathura R; Seaton KE; Zhang L; Hill J; Jones E; Alam SM; Dennison SM; Pollard AJ; Tomaras GD
Front Immunol; 2019; 10():2582. PubMed ID: 31781100
[TBL] [Abstract][Full Text] [Related]
7. Differential Killing of Salmonella enterica Serovar Typhi by Antibodies Targeting Vi and Lipopolysaccharide O:9 Antigen.
Hart PJ; O'Shaughnessy CM; Siggins MK; Bobat S; Kingsley RA; Goulding DA; Crump JA; Reyburn H; Micoli F; Dougan G; Cunningham AF; MacLennan CA
PLoS One; 2016; 11(1):e0145945. PubMed ID: 26741681
[TBL] [Abstract][Full Text] [Related]
8. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
[TBL] [Abstract][Full Text] [Related]
9. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
[TBL] [Abstract][Full Text] [Related]
10. Constitutive expression of the Vi polysaccharide capsular antigen in attenuated Salmonella enterica serovar typhi oral vaccine strain CVD 909.
Wang JY; Noriega FR; Galen JE; Barry E; Levine MM
Infect Immun; 2000 Aug; 68(8):4647-52. PubMed ID: 10899868
[TBL] [Abstract][Full Text] [Related]
11. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
Tacket CO; Pasetti MF; Sztein MB; Livio S; Levine MM
J Infect Dis; 2004 Aug; 190(3):565-70. PubMed ID: 15243933
[TBL] [Abstract][Full Text] [Related]
12. Reexamination of the protective role of the capsular polysaccharide (Vi antigen) of Salmonella typhi.
Robbins JD; Robbins JB
J Infect Dis; 1984 Sep; 150(3):436-49. PubMed ID: 6207249
[TBL] [Abstract][Full Text] [Related]
13. S.Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice.
Haque S; Sengupta S; Gupta D; Bhan MK; Kumar R; Khan A; Jailkhani B
Biologicals; 2019 Nov; 62():50-56. PubMed ID: 31606267
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines--a randomized trial.
Kantele A; Pakkanen SH; Karttunen R; Kantele JM
PLoS One; 2013; 8(4):e60583. PubMed ID: 23593253
[TBL] [Abstract][Full Text] [Related]
15. Protection in a mouse peritonitis model mediated by iron-regulated outer-membrane protein of Salmonella typhi coupled to its Vi antigen.
Chibber S; Bhardwaj SB
J Med Microbiol; 2004 Jul; 53(Pt 7):705-709. PubMed ID: 15184544
[TBL] [Abstract][Full Text] [Related]
16. Short Vi-polysaccharide abrogates T-independent immune response and hyporesponsiveness elicited by long Vi-CRM
Micoli F; Bjarnarson SP; Arcuri M; Aradottir Pind AA; Magnusdottir GJ; Necchi F; Di Benedetto R; Carducci M; Schiavo F; Giannelli C; Pisoni I; Martin LB; Del Giudice G; MacLennan CA; Rappuoli R; Jonsdottir I; Saul A
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24443-24449. PubMed ID: 32900928
[TBL] [Abstract][Full Text] [Related]
17. An Unmutated IgM Response to the Vi Polysaccharide of
Pandya KD; Palomo-Caturla I; Walker JA; K Sandilya V; Zhong Z; Alugupalli KR
J Immunol; 2018 Jun; 200(12):4078-4084. PubMed ID: 29743315
[TBL] [Abstract][Full Text] [Related]
18. The porin OmpD from nontyphoidal Salmonella is a key target for a protective B1b cell antibody response.
Gil-Cruz C; Bobat S; Marshall JL; Kingsley RA; Ross EA; Henderson IR; Leyton DL; Coughlan RE; Khan M; Jensen KT; Buckley CD; Dougan G; MacLennan IC; López-Macías C; Cunningham AF
Proc Natl Acad Sci U S A; 2009 Jun; 106(24):9803-8. PubMed ID: 19487686
[TBL] [Abstract][Full Text] [Related]
19. Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever.
Cross DL; Verheul MK; Leipold MD; Obermoser G; Jin C; Jones E; Starr JS; Mohorianu I; Blohmke CJ; Maecker HT; Napolitani G; Hill J; Pollard AJ
Front Immunol; 2020; 11():574057. PubMed ID: 33424833
[TBL] [Abstract][Full Text] [Related]
20. [Conjugate vaccines against bacterial infections: typhoid fever].
Paniagua J; García JA; López CR; González CR; Isibasi A; Kumate J
Salud Publica Mex; 1992; 34(3):268-73. PubMed ID: 1377407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
